Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords

Tabla de Datos

Artículos Totales: 42


Institución: Centro de Estudios Reumatologicos
# Título Código Publicación Revista Indexación Revista Tipo de Documento Autores Año
1 Efficacy, Safety, And Pharmacodynamic Effects Of The Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (Gdc 0853) In Systemic Lupus Erythematosus: Results Of A Phase Ii, Randomized, Double Blind, Placebo Controlled Trial
DOI: 10.1002/ART.41811 		WoS: WOS:000687792400001 Scopus: SCOPUS_ID:85112064449 Arthritis & Rheumatology WOS
Scopus 		Article 2021
2 Long Term Efficacy And Safety Of Biosimilar Ct P10 Versus Innovator Rituximab In Rheumatoid Arthritis: 48 Week Results From A Randomized Phase Iii Trial
DOI: 10.1007/S40259-018-00331-4 		WoS: WOS:000458935400007 Scopus: SCOPUS_ID:85061185514 Biodrugs WOS
Scopus 		Article 2019
3 Efficacy And Safety Of Switching From Rituximab To Biosimilar Ct P10 In Rheumatoid Arthritis: 72 Week Data From A Randomized Phase 3 Trial
DOI: 10.1093/RHEUMATOLOGY/KEZ152 		WoS: WOS:000501736300022 Scopus: SCOPUS_ID:85070068083 Rheumatology WOS
Scopus 		Article 2019
4 Comparison Of Biosimilar Ct P10 And Innovator Rituximab In Patients With Rheumatoid Arthritis: A Randomized Controlled Phase 3 Trial
DOI: 10.1080/19420862.2018.1487912 		WoS: WOS:000444570200011 Scopus: SCOPUS_ID:85050005180 M Abs WOS
Scopus 		Article 2018
5 Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Monoclonal Antibody Long Term Safety And Efficacy In Patients With Rheumatoid Arthritis
DOI: 10.1002/ART.40420 		WoS: WOS:000430912600007 Scopus: SCOPUS_ID:85044627852 Arthritis & Rheumatology WOS
Scopus 		Article 2018
6 Results Of A Longitudinal Review Of Pulmonary Function And Safety Data In A Phase Iib Clinical Programme Testing Granulocyte Macrophage Colony Stimulating Factor (Gm Csf) Receptor Antagonist Mavrilimumab For Treatment Of Rheumatoid Arthritis (Ra)
DOI: 10.1136/ANNRHEUMDIS-2017-EULAR.3131 		WoS: WOS:000413181401616 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2017
7 Randomised Double Blind Study Shows Comparable Long Term Efficacy And Safety Between Rituximab Biosimilar Ct P10 And Innovator Rituximab In Patients With Rheumatoid Arthritis: 48 Week Results
DOI: 10.1136/ANNRHEUMDIS-2017-EULAR.6553 		WoS: WOS:000413181402440 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2017
8 Efficacy And Safety Of Rituximab Biosimilar, Ct P10, After A Single Switch From Innovator Rituximabs In Patients With Rheumatoid Arthritis: Results From Phase 3 Randomized Controlled Trial Over 72 Weeks
WoS: WOS:000411824105287 Arthritis & Rheumatology WOS
Meeting Abstract 2017
9 Tofacitinib, An Oral Janus Kinase Inhibitor, For The Treatment Of Latin American Patients With Rheumatoid Arthritis: Pooled Efficacy And Safety Analyses Of Phase 3 And Long Term Extension Studies
DOI: 10.1016/J.REUMA.2016.04.010 		WoS: WOS:000408060800002 Scopus: SCOPUS_ID:85006470270 Reumatologia Clinica WOS
Scopus 		Article 2017
10 Transancestral Mapping And Genetic Load In Systemic Lupus Erythematosus
DOI: 10.1038/NCOMMS16021 		WoS: WOS:000405680100001 Scopus: SCOPUS_ID:85024906085 Nature Communications WOS
Scopus 		Article 2017
11 Efficacy And Safety Of Switching From Reference Infliximab To Ct P13 Compared With Maintenance Of Ct P13 In Ankylosing Spondylitis: 102 Week Data From The Planetas Extension Study
DOI: 10.1136/ANNRHEUMDIS-2015-208783 		WoS: WOS:000392426900005 Scopus: SCOPUS_ID:84965014483 Annals Of The Rheumatic Diseases WOS
Scopus 		Article 2017
12 Efficacy And Safety Of Ct P13 (Biosimilar Infliximab) In Patients With Rheumatoid Arthritis: Comparison Between Switching From Reference Infliximab To Ct P13 And Continuing Ct P13 In The Planetra Extension Study
DOI: 10.1136/ANNRHEUMDIS-2015-208786 		WoS: WOS:000392426900006 Scopus: SCOPUS_ID:84966417145 Annals Of The Rheumatic Diseases WOS
Scopus 		Article 2017
13 Earth Explorer 2, A Phase I Ib Exploratory Study Evaluating Efficacy And Safety Of Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Monoclonal Antibody, And The Tumor Necrosis Factor Antagonist Golimumab In Rheumatoid Arthritis
WoS: WOS:000417143402435 Arthritis & Rheumatology WOS
Meeting Abstract 2016
14 Effect Of Macitentan On The Development Of New Ischemic Digital Ulcers In Patients With Systemic Sclerosis: Dual 1 And Dual 2 Randomized Clinical Trials
DOI: 10.1001/JAMA.2016.5258 		Scopus: SCOPUS_ID:84968808222 Jama Journal Of The American Medical Association Scopus 2016
15 Results Of A Comprehensive Review Of Pulmonary Function And Safety Data In A Phase I Ib Clinical Program Testing Anti Gm Csf Receptor Antagonist Mavrilimumab For Treatment Of Ra
WoS: WOS:000417143404281 Arthritis & Rheumatology WOS
Meeting Abstract 2016
16 Genome Wide Association Study In An Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci And The Role Of European Admixture
DOI: 10.1002/ART.39504 		WoS: WOS:000373130300019 Scopus: SCOPUS_ID:84962045963 Arthritis & Rheumatology WOS
Scopus 		Article 2016
17 Efficacy And Safety Of Sarilumab Plus Mtx In Subgroups Of Patients With Rheumatoid Arthritis In A Phase 3 Study
WoS: WOS:000375046500122 Internal Medicine Journal WOS
Meeting Abstract 2016
18 Consistency Of Radiographic Responses With Sarilumab Plus Methotrexate Across Subpopulations Of Patients With Rheumatoid Arthritis In A Phase 3 Study
DOI: 10.1136/ANNRHEUMDIS-2016-EULAR.4363 		WoS: WOS:000401523103261 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2016
19 Efficacy And Safety Of Ct P10, Rituximab Biosimilar Candidate, And Innovator Rituximab In Patients With Rheumatoid Arthritis: Results From Phase 3 Randomized Controlled Trial Over 24 Weeks
WoS: WOS:000417143402451 Arthritis & Rheumatology WOS
Meeting Abstract 2016
20 Pharmacokinetics And Safety Of Three Formulations Of Rituximab (Ct P10, Us Sourced Innovator Rituximab And Eu Sourced Innovator Rituximab) In Patients With Rheumatoid Arthritis: Results From Phase 3 Randomized Controlled Trial Over 24 Weeks
WoS: WOS:000417143402450 Arthritis & Rheumatology WOS
Meeting Abstract 2016
21 Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Monoclonal Antibody: Long Term Safety And Efficacy For Up To 158 Weeks Of Treatment In Patients With Rheumatoid Arthritis
WoS: WOS:000417143402432 Arthritis & Rheumatology WOS
Meeting Abstract 2016
22 Long Term Safety And Efficacy Of Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Monoclonal Antibody, In Patients With Rheumatoid Arthritis
DOI: 10.1136/ANNRHEUMDIS-2016-EULAR.3498 		WoS: WOS:000401523102319 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2016
23 Earth Explorer 2, A Phase Iib Exploratory Study Evaluating Efficacy And Safety Of Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha Monoclonal Antibody, And The Tumor Necrosis Factor Antagonist Golimumab In Rheumatoid Arthritis
DOI: 10.1136/ANNRHEUMDIS-2016-EULAR.3453 		WoS: WOS:000401523103349 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2016
24 Genomic Insights Into The Ancestry And Demographic History Of South America
DOI: 10.1371/JOURNAL.PGEN.1005602 		WoS: WOS:000368518400002 Scopus: SCOPUS_ID:84953211197 P Lo S Genetics WOS
Scopus 		Article 2015
25 Long Term Safety And Efficacy Of Mavrilimumab, A Fully Human Granulocyte Macrophage Colony Stimulating Factor Receptor Alpha (Gm Csfr Alpha) Monoclonal Antibody, In Patients With Rheumatoid Arthritis (Ra)
WoS: WOS:000370860204660 Arthritis & Rheumatology WOS
Meeting Abstract 2015
26 Efficacy And Safety Of Sarilumab Plus Mtx In Subgroups Of Patients With Rheumatoid Arthritis In A Phase 3 Study
WoS: WOS:000370860204311 Arthritis & Rheumatology WOS
Meeting Abstract 2015
27 Efficacy And Safety/Tolerability Of Mavrilimumab, A Human Gm Csf Ra Monoclonal Antibody In Patients With Rheumatoid Arthritis.
WoS: WOS:000344384906056 Arthritis & Rheumatology WOS
Meeting Abstract 2014
28 Therapeutic Vaccination With Tnf Kinoid In Tnf Antagonist Resistant Rheumatoid Arthritis: A Phase Ii Randomized, Controlled Clinical Trial
DOI: 10.1371/JOURNAL.PONE.0113465 		WoS: WOS:000347215600004 Scopus: SCOPUS_ID:84919467063 P Lo S One WOS
Scopus 		Article 2014
29 The Rate Of Positive Conversion In The Quantiferon Tb Gold Test Over 2 Years Among Patients Treated With Ct P13 Or Innovator Infliximab In The Extension Studies Of Planetas And Planetra
DOI: 10.1136/ANNRHEUMDIS-2014-EULAR.3492 		WoS: WOS:000346919802385 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2014
30 Rapid Onset Of Clinical Benefit Is Associated With A Reduction In Validated Biomarkers Of Disease In Patients With Rheumatoid Arthritis Treated With Mavrilimumab, A Human Monoclonal Antibody Targeting Gm Csf Ra
WoS: WOS:000344384903110 Arthritis & Rheumatology WOS
Meeting Abstract 2014
31 Inhibition Of Radiographic Progression And Its Association With Clinical Parameters In Ra Patients Treated With Ct P13 And Innovator Infliximab In Planetra Study
DOI: 10.1136/ANNRHEUMDIS-2014-EULAR.3056 		WoS: WOS:000346919801175 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2014
32 Improvements In Physical Function, Health Related Quality Of Life And Work Productivity In Patients With Rheumatoid Arthritis Treated With Golimumab: Sub Analysis Of Latin American Patients Enrolled In Mulitcentre Phase Iii Clinical Trials
DOI: 10.1016/J.JVAL.2013.08.2230 		WoS: WOS:000326247603305 Value In Health WOS
Meeting Abstract 2013
33 Final 5 Year Safety And Efficacy Results Of A Phase 3, Randomized Placebo Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
WoS: WOS:000325359203395 Arthritis And Rheumatism WOS
Meeting Abstract 2013
34 Gwas In Hispanic And Latin American Individuals Enriched For Amerindian Ancestry Identifies A New Locus Associated With Systemic Lupus Erythematosus
WoS: WOS:000325359204103 Arthritis And Rheumatism WOS
Meeting Abstract 2013
35 A Randomised, Double Blind, Multicentre, Parallel Group, Prospective Study Comparing The Pharmacokinetics, Safety, And Efficacy Of Ct P13 And Innovator Infliximab In Patients With Ankylosing Spondylitis: The Planetas Study
DOI: 10.1136/ANNRHEUMDIS-2012-203091 		WoS: WOS:000323906000005 Scopus: SCOPUS_ID:84883746909 Annals Of The Rheumatic Diseases WOS
Scopus 		Article 2013
36 A Randomised, Double Blind, Parallel Group Study To Demonstrate Equivalence In Efficacy And Safety Of Ct P13 Compared With Innovator Infliximab When Coadministered With Methotrexate In Patients With Active Rheumatoid Arthritis: The Planetra Study
DOI: 10.1136/ANNRHEUMDIS-2012-203090 		WoS: WOS:000323906000006 Scopus: SCOPUS_ID:84883752718 Annals Of The Rheumatic Diseases WOS
Scopus 		Article 2013
37 A Randomized, Double Blind, Phase 3 Study Demonstrates Clinical Equivalence Of Ct P13 To Infliximab When Co Administered With Methotrexate In Patients With Active Rheumatoid Arthritis
DOI: 10.1136/ANNRHEUMDIS-2012-EULAR.2600 		WoS: WOS:000208898502034 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2013
38 Active Therapeutic Immunization With Tnf Kinoid In Rheumatoid Arthritis Patients With Secondary Resistance To Tnf Alpha Antagonists Is Safe And Immunogenic
DOI: 10.1136/ANNRHEUMDIS-2012-EULAR.2609 		WoS: WOS:000208898502043 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2013
39 A Randomized, Double Blind, Phase 1 Study Demonstrates Equivalence In Pharmacokinetics, Safety, And Efficacy Of Ct P13 And Infliximab In Patients With Ankylosing Spondylitis
DOI: 10.1136/ANNRHEUMDIS-2012-EULAR.1850 		WoS: WOS:000208898500372 Annals Of The Rheumatic Diseases WOS
Meeting Abstract 2013
40 Efficacy And Safety Of Ct P13 (Infliximab Biosimilar) Over Two Years In Patients With Ankylosing Spondylitis: Comparison Between Continuing With Ct P13 And Switching From Infliximab To Ct P13
WoS: WOS:000327692600055 Arthritis And Rheumatism WOS
Meeting Abstract 2013
41 Active Immunization With Tnf Kinoid In Rheumatoid Arthritis Patients With Secondary Resistance To Tumor Necrosis Factor Alpha Antagonists Is Safe And Immunogenic
WoS: WOS:000309748301018 Arthritis And Rheumatism WOS
Meeting Abstract 2012
42 Active Therapeutic Immunization With Tnf Kinoid In Patients With Rheumatoid Arthritis With Secondary Resistance To A Tnfa Monoclonal Antibody
WoS: WOS:000291358900655 Inflammation Research WOS
Meeting Abstract 2011
Descargar Descarga los datos (enriquecidos) de esta página (formato CSV).









Departamento Gestión de Conocimiento, Monitoreo y Prospección
 Moneda 1375, Santiago de Chile. Teléfono (56 2) 2365 4400
Consultas o comentarios: productividad@anid.cl